drugset / Trial / NCT01391312

Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines

NCT01391312

Phase 4 Completed 40 enrolled Allergan
RandomizedParallel-groupTriple-blindTreatment

Summary

This was a pilot study to observe patient satisfaction with BOTOX® Cosmetic treatment in glabellar rhytides (frown lines) using a new treatment satisfaction measure.

Timeline

Start
2011-06
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 20 iu

Indications

No indication recorded.